Pharmacogenetics of coumarinic oral anticoagulants

Pharmacogenomics

Volumn 11, Issue 4, 2010, Pages 493-496

  Manolopoulos, Vangelis G ^a   Ragia, Georgia ^a   Tavridou, Anna ^a  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

Author keywords

Acenocoumarol; CYP2C9 polymorphism; Oral anticoagulant; Pharmacogenetics; Phenprocoumon; VKORC1 polymorphism; Warfarin

Indexed keywords

COUMARIN; CYTOCHROME P450 2C9; MENADIONE EPOXIDE; UNCLASSIFIED DRUG; VITAMIN K EPOXIDE REDUCTASE COMPLEX SUBUNIT 1; WARFARIN;

ACCURACY; ALGORITHM; COST EFFECTIVENESS ANALYSIS; DNA POLYMORPHISM; DRUG SAFETY; ENZYME ACTIVITY; GENE FREQUENCY; GENE MUTATION; GENETIC VARIABILITY; GENOTYPE; MAINTENANCE DRUG DOSE; NOTE; PHARMACOGENOMICS; PREDICTION;

ANTICOAGULANTS; ARYL HYDROCARBON HYDROXYLASES; COUMARINS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MIXED FUNCTION OXYGENASES; PHARMACOGENETICS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 77950353192     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.10.31     Document Type: Note

References (20)

1. Pirmohamed M: Warfarin: almost 60 years old and still causing problems. The Scylla and Charybdis of oral anticoagulant treatment. Br. J. Clin. Pharmacol. 62, 509-511 (2006).
2. James AH, Britt R P, Raskino CL, Thompson SG: Factors affecting the maintenance dose of warfarin. J. Clin. Pathol. 45, 704-706 (1992).
3. Bodin L, Verstuyft C, Tregouet DA et al.: Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity. Blood 106, 135-140 (2005).
4. Schalekamp T, Brasse BP, Roijers JF et al.: VKORC1 and CYP2C9 genotypes and phenprocoumon anticoagulation status: interaction between both genotypes affects dose requirement. Clin. Pharmacol. Ther. 81, 185-193 (2007).
5. Wadelius M, Chen LY, Lindh JD et al.: The largest prospective warfarin-treated cohort supports genetic forecasting. Blood 113, 784-792 (2009).
6. Stehle S, Kirchheiner J, Lazar A, Fuhr U: Pharmacogenetics of oral anticoagulants: a basis for dose individualization. Clin. Pharmacokinet. 47, 565-594 (2008).
7. Aithal GP, Day CP, Kesteven PJ, Daly AK: Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 353, 717-719 (1999).
8. Rost S, Fregin A, Ivaskevicius V et al.: Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor defciency type 2. Nature 427, 537-541 (2004).
9. Yang L, Ge W, Yu F, Zhu H: Impact of VKORC1 gene polymorphism on interindividual and interethnic warfarin dosage requirement-a systematic review and meta analysis. Thromb. Res. (2010) (Epub ahead of print).
10. Sconce EA, Khan TI, Wynne HA et al.: The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood. 106, 2329-2333 (2005).
11. Gage B, Eby C, Johnson J et al.: Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin. Pharmacol. Ther. 84, 326-331 (2008)
12. The International Warfarin Pharmacogenetics Consortium: Estimation of the warfarin dose with clinical and pharmacogenetic data. N. Engl. J. Med. 360, 753-764 (2009).
13. Hillman MA, Wilke RA, Yale SH et al.: A prospective, randomized pilot trial of model-based warfarin dose initiation using CYP2C9 genotype and clinical data. Clin. Med. Res. 3, 137-145 (2005).
14. Caraco Y, Blotnick S, Muszkat M: CYP2C9 genotype-guided warfarin prescribing enhances the effcacy and safety of anticoagulation: a prospective randomized controlled study. Clin. Pharmacol. Ther. 83, 460-470 (2008).
15. Anderson JL, Horne BD, Stevens SM et al.: Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation 116, 2563-2570 (2007).
16. Schwarz UI, Ritchie MD, Bradford Y et al.: Genetic determinants of response to warfarin during initial anticoagulation. N. Engl. J. Med. 358, 999-1008 (2008).
17. van Schie RM, Wadelius MI, Kamali F et al.: Genotype-guided dosing of coumarin derivatives: the European pharmacogenetics of anticoagulant therapy (EU-PACT) trial design. Pharmacogenomics 10, 1687-1695 (2009).
18. Ansell J, Hirsh J, Hylek E et al.: Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133, S160-S198 (2008).
19. Takeuchi F, McGinnis R, Bourgeois S et al.: A genome-wide association study confrms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet. 5, E1000433 (2009).
20. Connolly SJ, Ezekowitz MD, Yusuf S et al.: Dabigatran versus warfarin in patients with atrial fbrillation. N. Engl. J. Med. 361, 1139-1151 (2009).